Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool, which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA) and computed tomography angiography (CTA). The CSS is non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers.


TSXV:CVM.H - Post by User

Bullboard Posts
Post by Looneytuneson Aug 10, 2019 1:08pm
145 Views
Post# 30014614

Focus on the size of the prize

Focus on the size of the prize
While we are all entitlied to our own opinions, in mine as long as you accept that this is a speculative stock, then there is obsolutely no reason for any negativity whatsoever.
If you discount the facts that perhaps the management should have confirmed that the data being submitted with the FDA application exactly met thier requirements, and the somewhat immoral relationship between CVR Medical and CVR Global; ie both having exactly the same management team allowing them to shamelessly move profit away from shareholders and directly into their own pockets, then operationally this team hasn't put a foot wrong. And btw, I'd expect this relationship issue to be resolved in short order.
We have a product that is not only top of class but that is almost in a class of it's own, quicker, cheaper and more accurate than anything else on the market. A product that, through a very intelligent partnership with Canon, one of the most experienced medical device distributers in the world, is about to be launched GLOBALLY - pretty well all of the information given out by the company so far has focussed on the US, but as many Americans tend to forget; the world is much, much bigger. The investor presentation talks about the U.S. being a $12.5b opportunity - multiply that by the rest of the world, and what figure do you get - I've no clue but it must be absolutely HUGE !!!
I'm sure that the FDA application must be sorted by the end of the year; yes probably a 5/6 month delay on what we originally thought but personally, I'd rather the FDA get it absolutely right, and with the 'size of the prize; whats 6 months in the grand scheme of things. Most of my other investments are in mining stocks and the definition of the word 'imminent' usually means in excess of 12 months, so 6 months is completely acceptable. I for one am really looking forward to 2020!!
Bullboard Posts